263 related articles for article (PubMed ID: 20148560)
21. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases.
Malcomson T; Yelekci K; Borrello MT; Ganesan A; Semina E; De Kimpe N; Mangelinckx S; Ramsay RR
FEBS J; 2015 Aug; 282(16):3190-8. PubMed ID: 25755053
[TBL] [Abstract][Full Text] [Related]
22. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
23. Structure activity relationship and modeling studies of inhibitors of lysine specific demethylase 1.
Zhou C; Wu F; Lu L; Wei L; Pai E; Yao Y; Song Y
PLoS One; 2017; 12(2):e0170301. PubMed ID: 28158205
[TBL] [Abstract][Full Text] [Related]
24. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
25. Development and Structural Evaluation of N-Alkylated trans-2-Phenylcyclopropylamine-Based LSD1 Inhibitors.
Niwa H; Sato S; Handa N; Sengoku T; Umehara T; Yokoyama S
ChemMedChem; 2020 May; 15(9):787-793. PubMed ID: 32166890
[TBL] [Abstract][Full Text] [Related]
26. Discovery of new tranylcypromine derivatives as highly potent LSD1 inhibitors.
Huang MJ; Guo JW; Fu YD; You YZ; Xu WY; Song TY; Li R; Chen ZT; Huang LH; Liu HM
Bioorg Med Chem Lett; 2021 Jun; 41():127993. PubMed ID: 33775841
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide.
Kakizawa T; Mizukami T; Itoh Y; Hasegawa M; Sasaki R; Suzuki T
Bioorg Med Chem Lett; 2016 Feb; 26(4):1193-5. PubMed ID: 26794039
[TBL] [Abstract][Full Text] [Related]
28. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation.
Yang M; Culhane JC; Szewczuk LM; Gocke CB; Brautigam CA; Tomchick DR; Machius M; Cole PA; Yu H
Nat Struct Mol Biol; 2007 Jun; 14(6):535-9. PubMed ID: 17529991
[TBL] [Abstract][Full Text] [Related]
29. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
Lee MG; Wynder C; Schmidt DM; McCafferty DG; Shiekhattar R
Chem Biol; 2006 Jun; 13(6):563-7. PubMed ID: 16793513
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
31. A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1.
Forneris F; Binda C; Dall'Aglio A; Fraaije MW; Battaglioli E; Mattevi A
J Biol Chem; 2006 Nov; 281(46):35289-95. PubMed ID: 16987819
[TBL] [Abstract][Full Text] [Related]
32. Identification of selective and reversible LSD1 inhibitors with anti-metastasis activity by high-throughput docking.
Li L; Li R; Wang Y
Bioorg Med Chem Lett; 2019 Feb; 29(4):544-548. PubMed ID: 30611617
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Vianello P; Botrugno OA; Cappa A; Ciossani G; Dessanti P; Mai A; Mattevi A; Meroni G; Minucci S; Thaler F; Tortorici M; Trifiró P; Valente S; Villa M; Varasi M; Mercurio C
Eur J Med Chem; 2014 Oct; 86():352-63. PubMed ID: 25173853
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
35. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
37. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.
Gooden DM; Schmidt DM; Pollock JA; Kabadi AM; McCafferty DG
Bioorg Med Chem Lett; 2008 May; 18(10):3047-51. PubMed ID: 18242989
[TBL] [Abstract][Full Text] [Related]
38. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
39. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
40. New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells.
Hoang N; Zhang X; Zhang C; Vo V; Leng F; Saxena L; Yin F; Lu F; Zheng G; Bhowmik P; Zhang H
Bioorg Med Chem; 2018 May; 26(8):1523-1537. PubMed ID: 29439916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
